DOP2024000005A - Composiciones, métodos y sistemas para la administración de fármacos en aerosol - Google Patents

Composiciones, métodos y sistemas para la administración de fármacos en aerosol

Info

Publication number
DOP2024000005A
DOP2024000005A DO2024000005A DO2024000005A DOP2024000005A DO P2024000005 A DOP2024000005 A DO P2024000005A DO 2024000005 A DO2024000005 A DO 2024000005A DO 2024000005 A DO2024000005 A DO 2024000005A DO P2024000005 A DOP2024000005 A DO P2024000005A
Authority
DO
Dominican Republic
Prior art keywords
compositions
systems
methods
acting
aerosol
Prior art date
Application number
DO2024000005A
Other languages
English (en)
Inventor
Lechuga-Ballesteros David
JOSHI Vidya
ARCHBELL James
LACHACZ Kellisa
LAMPA Charina
GUTIERREZ Gertrude
MELLO Lauren
TAN Penny
Riebe Michael
Original Assignee
Astrazeneca Pharmaceuticals Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Pharmaceuticals Lp filed Critical Astrazeneca Pharmaceuticals Lp
Publication of DOP2024000005A publication Critical patent/DOP2024000005A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/16—Fluorine compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan composiciones, métodos y sistemas para la administración pulmonar 5 de agentes activos mediante un inhalador de dosis medida. En algunas modalidades, las composiciones comprenden un medio de suspensión HFO-1234ze(E), partículas de agente activo y partículas suspendidas. Las partículas de agente activo pueden comprender uno, dos, tres o cuatro agentes activos seleccionados entre un antagonista muscarínico de acción prolongada (LAMA), un agonista P2 de acción 10 prolongada (LABA), un agonista beta de acción corta (SABA), un corticoide inhalado (ICS) y un agente antiinflamatorio no corticoide.
DO2024000005A 2021-07-09 2024-01-04 Composiciones, métodos y sistemas para la administración de fármacos en aerosol DOP2024000005A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163220362P 2021-07-09 2021-07-09
US202163282356P 2021-11-23 2021-11-23
PCT/US2022/036542 WO2023283438A1 (en) 2021-07-09 2022-07-08 Compositions, methods and systems for aerosol drug delivery

Publications (1)

Publication Number Publication Date
DOP2024000005A true DOP2024000005A (es) 2024-04-15

Family

ID=82748203

Family Applications (3)

Application Number Title Priority Date Filing Date
DO2024000004A DOP2024000004A (es) 2021-07-09 2024-01-03 Composiciones, métodos y sistemas para la administración de fármacos en aerosol
DO2024000005A DOP2024000005A (es) 2021-07-09 2024-01-04 Composiciones, métodos y sistemas para la administración de fármacos en aerosol
DO2024000006A DOP2024000006A (es) 2021-07-09 2024-01-05 Composiciones, métodos y sistemas para la administración de fármacos en aerosol

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DO2024000004A DOP2024000004A (es) 2021-07-09 2024-01-03 Composiciones, métodos y sistemas para la administración de fármacos en aerosol

Family Applications After (1)

Application Number Title Priority Date Filing Date
DO2024000006A DOP2024000006A (es) 2021-07-09 2024-01-05 Composiciones, métodos y sistemas para la administración de fármacos en aerosol

Country Status (14)

Country Link
US (1) US20230026203A1 (es)
EP (4) EP4175620B1 (es)
KR (3) KR20240042437A (es)
AU (3) AU2022306682A1 (es)
CA (3) CA3226557A1 (es)
CO (3) CO2024000631A2 (es)
DK (3) DK4175619T3 (es)
DO (3) DOP2024000004A (es)
FI (2) FI4197528T3 (es)
IL (3) IL309888A (es)
LT (2) LT4197528T (es)
PE (2) PE20240807A1 (es)
TW (3) TW202317081A (es)
WO (3) WO2023283438A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023212191A1 (en) * 2022-04-28 2023-11-02 Astrazeneca Ab Combination of albuterol and budesonide for the treatment of asthma

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US37872A (en) 1863-03-10 Improved mast-hoop
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
GB1200886A (en) 1966-09-23 1970-08-05 Allen & Hanburys Ltd Phenylaminoethanol derivatives
US3994974A (en) 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
SE378109B (es) 1972-05-19 1975-08-18 Bofors Ab
US4187301A (en) 1978-04-05 1980-02-05 Syntex (U.S.A.) Inc. 17 Beta-thiocarboxylic acid esters of 6 alpha, 6 beta-difluoro-3-oxoandrost-4-enes
JPS56138200A (en) 1980-02-15 1981-10-28 Glaxo Group Ltd Androstane carbothioate compound
DE3260474D1 (en) 1981-02-02 1984-09-06 Schering Corp Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
ZW6584A1 (en) 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
US5707634A (en) 1988-10-05 1998-01-13 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
GB8903593D0 (en) 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
US5610163A (en) 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
AU659645B2 (en) 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
SE9404080L (sv) 1993-12-28 1995-06-29 Ciba Geigy Ag Förfarande för framställning av en optiskt ren enantiomer av formoterol
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
DE4440337A1 (de) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
JP3708553B2 (ja) 1995-04-14 2005-10-19 ネクター セラピューティクス 向上した分散性を有する粉末型薬理組成物
US6258341B1 (en) 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
US5833891A (en) 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
US5886200A (en) 1996-07-01 1999-03-23 Schering Corporation Process for the preparation of 17-esters of 9 α, 21-dihalo-pregnane-11 β, 17 α-diol-20-ones
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
US6010935A (en) 1997-08-21 2000-01-04 Micron Technology, Inc. Self aligned contacts
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
PT102343B (pt) 1999-08-02 2003-11-28 Hovione Farmaciencia Sa Processo para a preparacao de furoato mometasona
EP1666028B1 (en) 1999-10-29 2010-03-24 Novartis AG Dry powder compositions having improved dispersivity
US7442388B2 (en) 2000-05-10 2008-10-28 Weers Jeffry G Phospholipid-based powders for drug delivery
US6908928B2 (en) 2000-10-12 2005-06-21 Bi Pharma Kg. Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
US7550133B2 (en) * 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
CN100471840C (zh) 2003-03-10 2009-03-25 尼科梅德有限责任公司 制备罗氟司特的方法
EP1635786A2 (en) 2003-05-28 2006-03-22 Nektar Therapeutics Spray drying of an alcoholic aqueous solution for the manufacture of a water-insoluble active agent microparticle with a partial or complete amino acid and/or phospholipid coat
WO2007009164A1 (en) 2005-07-15 2007-01-25 Eiffel Technologies Limited Method of particle formation
CN100560598C (zh) 2005-07-26 2009-11-18 上海奥锐特国际贸易有限公司 氟替卡松丙酸酯的合成方法
US8815258B2 (en) * 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
EP3106149B1 (en) 2009-05-29 2019-11-20 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting beta-2 adrenergic receptor agonists and associated methods and systems
EP2709447A4 (en) * 2011-05-17 2014-10-22 Pearl Therapeutics Inc COMPOSITIONS, METHODS AND SYSTEMS FOR RESPIRATORY ADMINISTRATION OF AT LEAST TWO ACTIVE AGENTS
EP2776395A2 (en) 2011-11-09 2014-09-17 Mylan Laboratories, Limited Process for the preparation of roflumilast
WO2013130767A1 (en) * 2012-02-29 2013-09-06 Pulmatrix, Inc. Inhalable dry powders
EP2909177B1 (en) 2012-10-17 2017-03-29 Interquim, S.A. Process for preparing roflumilast
WO2014115127A1 (en) * 2013-01-28 2014-07-31 Incozen Therapeutics Pvt. Ltd. Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide
RU2015154720A (ru) * 2013-05-22 2017-06-27 Перл Терапьютикс, Инк. Композиции, способы и системы для респираторной доставки трех или более активных средств
ES2921305T3 (es) 2017-10-09 2022-08-23 Pearl Therapeutics Inc Sistemas de administración de fármaco

Also Published As

Publication number Publication date
AU2022305962A1 (en) 2024-01-25
CO2024000748A2 (es) 2024-02-26
EP4175620A1 (en) 2023-05-10
WO2023283441A1 (en) 2023-01-12
PE20240808A1 (es) 2024-04-18
CA3226557A1 (en) 2023-01-12
US20230026203A1 (en) 2023-01-26
LT4197528T (lt) 2024-06-10
DK4175620T3 (da) 2024-06-03
KR20240042437A (ko) 2024-04-02
FI4197528T3 (fi) 2024-05-24
CO2024000631A2 (es) 2024-02-15
KR20240042436A (ko) 2024-04-02
KR20240042438A (ko) 2024-04-02
DK4197528T3 (da) 2024-05-06
AU2022308837A1 (en) 2024-01-25
DOP2024000006A (es) 2024-04-15
DK4175619T3 (da) 2024-05-06
EP4366695A1 (en) 2024-05-15
FI4175619T3 (fi) 2024-05-28
EP4197528B1 (en) 2024-04-03
AU2022306682A1 (en) 2024-01-25
WO2023283438A1 (en) 2023-01-12
TW202317080A (zh) 2023-05-01
WO2023283439A1 (en) 2023-01-12
EP4197528A1 (en) 2023-06-21
IL309888A (en) 2024-03-01
EP4175619B1 (en) 2024-04-10
CA3226155A1 (en) 2023-01-12
TW202317081A (zh) 2023-05-01
EP4175620B1 (en) 2024-04-10
CO2024000742A2 (es) 2024-02-26
PE20240807A1 (es) 2024-04-18
TW202317079A (zh) 2023-05-01
IL309907A (en) 2024-03-01
IL309908A (en) 2024-03-01
CA3226153A1 (en) 2023-01-12
EP4175619A1 (en) 2023-05-10
DOP2024000004A (es) 2024-04-15
LT4175619T (lt) 2024-06-10

Similar Documents

Publication Publication Date Title
DOP2024000005A (es) Composiciones, métodos y sistemas para la administración de fármacos en aerosol
Gan et al. Intravenous amisulpride for the prevention of postoperative nausea and vomiting: two concurrent, randomized, double-blind, placebo-controlled trials
Nathan et al. Once daily fluticasone propionate aqueous nasal spray is an effective treatment for seasonal allergic rhinitis.
AR038644A1 (es) Formulaciones hfa de agonistas beta-2 de derivados de 2 (1h)-quinolinona de accion prolongada
Le Cesne et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial
Daley‐Yates et al. Therapeutic index of inhaled corticosteroids in asthma: A dose–response comparison on airway hyperresponsiveness and adrenal axis suppression
Bur et al. Drug transport across pulmonary epithelial cell monolayers: effects of particle size, apical liquid volume, and deposition technique
Braunstein et al. Why wait? The case for treating tuberculosis with inhaled drugs
AR038643A1 (es) Formulaciones en aerosol para la administracion pulmonar de medicamentos que producen un efecto sistemico
DK1257254T3 (da) Formuleringer indeholdende et anticholinergt lægemiddel til behandling af kronisk obstruktiv lungesygdom
RU2006132195A (ru) Комбинация агонистов бета-2 адренорецептора, бензотиазол-2-онов и кортикостероидов, предназначенная для лечения респираторных заболеваний
JP2019528316A5 (es)
Beeh et al. Pharmacodynamics and pharmacokinetics following once-daily and twice-daily dosing of tiotropium Respimat® in asthma using standardized sample-contamination avoidance
Hooten et al. Serum triamcinolone levels following interlaminar epidural injection
Zhu et al. The formulation of a pressurized metered dose inhaler containing theophylline for inhalation
Beier et al. Abediterol, a novel long-acting β 2-agonist: bronchodilation, safety, tolerability and pharmacokinetic results from a single-dose, dose-ranging, active-comparator study in patients with COPD
AR126412A1 (es) Composiciones, métodos y sistemas para la administración de fármacos en aerosol
Martinez-Guerrero et al. Cationic Compounds with SARS-CoV-2 Antiviral Activity and Their Interaction with Organic Cation Transporter/Multidrug and Toxin Extruder Secretory Transporters
Bleecker et al. Proventil HFA and Ventolin have similar safety profiles during regular use
CN101951886A (zh) 增强羟甲唑啉的光稳定性
NO20074854L (no) Farmasoytiske aerosolformuleringer for komprimerte, utmalte doseinhalatorer omfattende et sekvestreringsmiddel
Ambery et al. Open‐Label, Crossover Study to Determine the Pharmacokinetics of Fluticasone Furoate and Batefenterol When Administered Alone, in Combination, or Concurrently
Kunka et al. From hydrofluoroalkane pressurized metered dose inhalers (pMDIs) and comparability with chlorofluorocarbon pMDIs.
Fokkens et al. The effect of intranasal and inhaled corticosteroids in healthy volunteers on the number of circulating lymphocytes and lymphocyte subsets
Anderson et al. Equivalent efficacy and safety of a new HFA-134a formulation of BDP compared with the conventional CFC in adult asthmatics.